Commercial Credit Report for Kolinpharma SpA

CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals. Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue. We also offer solutions that can help ease private company financial risk assessment. Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively.

A partial report preview for Kolinpharma SpA is shown below. Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database. To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

	Kolinpharma SpA
Corso Europa, 5
Phone: +39 02 94324300p:+39 02 94324300	LAINATE, 20020 Italy	Fax: +39 02 93571446f:+39 02 93571446

On 8/11/2023, the Company was acquired by Igea Holding Spa
This company is no longer actively traded on any major stock exchange.

Business Summary

Kolinpharma SpA is an Italy-based company specialized in the pharmaceutical industry. The Company offers a number of products, including almetax, which is a food supplement based on alpha-lipoic acid, L-tryptophan, turmeric, vitamins B5, b6 AND C, Chromium picolinade and Zinc that acts synergistically on the main symptoms of menopause; Almatex easy, which enables the preservation of the general well-being of the body; Dolasix, which is a food supplement that acts synergistically in favor of the normal functionality of cartilages and connective tissues; Ivuxur, which is a food supplement based on cranberry ( dried cranberry extract), D-mannose, bearberry and Zinc that is used in the treatment of unary tract infections; Milesax, which is a food supplement based on magnesium bisglycinate, boswellia serrata and L-tryptophan that acts synergistically on contractures, muscles relaxation and mood during the rehabilitation and recovery phases, and Xinepa, among others.

Scores and Ratings

FRISK^® Score	Z'' Score	PAYCE^® Score	DBT Index	Moody's Rating	Fitch Rating	DBRS Rating
-	Yes	-	-	-	-	-

Financials, News and Filings

Latest Statement	Last Audit	News	SEC Filings	Bankruptcy Filings	Suit & Judgment Filings	Tax Lien Filings
12/31/2022	12/31/2022	Yes	-	-	-	-

Industries

SIC Code	Description
2834	Pharmaceutical preparations
3845	Electromedical and electrotherapeutic apparatus

Officers and Directors

Title	Name	Age	Title Date	Start Date
Chairwomen of the Board, Chief Executive Officer, Chief Financial Officer	Rita P.Petrelli
Chief Executive Officer, Director	MassimoMantella
Non-Executive Director	GiannunzioCorazza
3 additional Officers and Directors records available in full report.

General Information

Number of Employees:	107	(As of 12/31/2022)
Outstanding Shares:	1,614,171	(As of 12/31/2022)
Stock Exchange:	BIT
Fax Number:	+39 02 93571446

SITE MAP | ABOUT US | DIRECTORY | STOCK QUOTE: CRMZ | SIGN IN